KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $44.7 million.

  • Co-Diagnostics' Liabilities and Shareholders Equity fell 3818.73% to $44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.4 million, marking a year-over-year decrease of 3722.12%. This contributed to the annual value of $64.0 million for FY2024, which is 3285.83% down from last year.
  • Per Co-Diagnostics' latest filing, its Liabilities and Shareholders Equity stood at $44.7 million for Q3 2025, which was down 3818.73% from $46.5 million recorded in Q2 2025.
  • Co-Diagnostics' Liabilities and Shareholders Equity's 5-year high stood at $171.2 million during Q1 2022, with a 5-year trough of $44.7 million in Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $101.4 million, with a median of $95.3 million in 2023.
  • As far as peak fluctuations go, Co-Diagnostics' Liabilities and Shareholders Equity surged by 29608.21% in 2021, and later crashed by 4242.26% in 2025.
  • Over the past 5 years, Co-Diagnostics' Liabilities and Shareholders Equity (Quarter) stood at $160.0 million in 2021, then fell by 23.09% to $123.1 million in 2022, then fell by 22.56% to $95.3 million in 2023, then plummeted by 32.86% to $64.0 million in 2024, then crashed by 30.09% to $44.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $44.7 million for Q3 2025, versus $46.5 million for Q2 2025 and $55.1 million for Q1 2025.